Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study assessed the utility of plasma fragments of propeptides of type III (PRO-C3), V (PRO-C5), and VI (PRO-C6) procollagen for the detection of liver fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: Patients with T2DM (n = 191) underwent an oral glucose tolerance test, a liver 1H-MRS, and a liver biopsy when indicated. PRO-C3, PRO-C5, and PRO-C6 were blindly assessed. RESULTS: PRO-C3 performed well for the diagnosis of moderate-to-advanced (area under the receiver operating characteristic curve [AUROC] 0.81 [95% CI 0.74–0.88]) and advanced (AUROC 0.88 [0.80–0.95]) fibrosis in T2DM patients. Its performance was similar to that of AST to platelet ratio index (APRI) (AUROC 0.83 and 0.87, respectively) and Fibrosis-4 (FIB-4) (AUROCs 0.83 and 0.86, respectively) scores. Use of PRO-C5 and PRO-C6 did not improve the accuracy to detect liver fibrosis. After 18 months, PRO-C3 changes were associated with changes in fibrosis stages. CONCLUSIONS: PRO-C3 performed well for the detection of fibrosis in T2DM patients and showed promising results for prediction of histological changes in fibrosis stage with treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo37.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [37]
Citations
Cites
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Self-citationManagement of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Self-citationBril, F., Biernacki, D. M., Kalavalapalli, S., Lomonaco, R., Subbarayan, S. K., Lai, J., Tio, F., Suman, A., Orsak, B. K., Hecht, J., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0167 · Cited by 312 · cited 1×
“Details and results from those randomized controlled trials have previously been published (13,14).”
BackgroundSelf-citationDaniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273 · cited 6×
“Only recently have efforts focused in a population exclusively of patients with T2DM, but results have been mixed and not widely embraced by health care providers (5,6).”
BackgroundSelf-citationBril, F., Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Freckleton, M., Chintapalli, K., Hardies, J., Lai, S., Solano, F., Tio, F., et al. (2015) · Liver International · doi:10.1111/liv.12840 · Cited by 237 · cited 1×
“Study Design All patients underwent proton MRS ((1)HMRS) to measure intrahepatic triglyceride content as previously reported (15), a 2-h OGTT (with blood collection every 30 min), and a percutaneous liver biopsy if patients had NAFLD.”
MethodSelf-citation(2013) · Europe PMC (PubMed Central) · Cited by 214
Self-citationBazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
Adams, L. A., George, J., Bugianesi, E., Rossi, E., De Boer, W. B., van der Poorten, D., Ching, H. L. I., Bulsara, M., & Jeffrey, G. P. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06774.x · Cited by 172
Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R., Goodman, Z. D., Schuppan, D., & Patel, K. (2015) · Liver International · doi:10.1111/liv.12700 · Cited by 144
Self-citation
Cited by
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationHartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
“direct marker of fibrogenesis and its use as a biomarker in those with type 2 diabetes can aid the identification of patients with moderately advanced and advanced fibrosis (34,35).”
BackgroundSanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
“Changes in pro-C3 have also been shown to correlate with changes in fibrosis stage in patients with T2D and MASLD after 18 months of treatment with pioglitazone, vitamin E or placebo 37 .”
BackgroundBril, F., McPhaul, M. J., Caulfield, M. P., Clark, V. C., Soldevilla-Pico, C., Firpi-Morell, R. J., Lai, J., Shiffman, D., Rowland, C. M., & Cusi, K. (2020) · Diabetes Care · doi:10.2337/dc19-1071 · Cited by 179
“Patients included in this analysis have been previously reported on in studies that focused on assessing the performance of plasma fragments of propeptide of type III procollagen (PRO-C3) (22), the FibroMax test (20), and OWLiver test (19) in patients with T2DM.”
BackgroundSelf-citationMetabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
Self-citationNielsen, M. J., Leeming, D. J., Goodman, Z. D., Friedman, S. L., Frederiksen, P., Rasmussen, D. G. K., Vig, P., Seyedkazemi, S., Fischer, L., Torstenson, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.016 · Cited by 79
“PRO-C3 has previously been reported to be a promising biomarker associated with the degree and dynamics of liver fibrosis.(9,10) PRO-C3 can predict progression of liver fibrosis and clinical outcomes,(11,12) and can also be used as a pharmacodynamic biomarker in metabolic and biliary liver diseases.”
BackgroundSelf-citationVillesen, I. F., Daniels, S. J., Leeming, D. J., Karsdal, M. A., & Nielsen, M. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15773 · Cited by 63
Self-citationCusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Self-citationMak, A. L., Lee, J., van Dijk, A., Vali, Y., Aithal, G. P., Schattenberg, J. M., Anstee, Q. M., Brosnan, M. J., Zafarmand, M. H., Ramsoekh, D., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9121920 · Cited by 53
Erhardtsen, E., Rasmussen, D. G. K., Frederiksen, P., Leeming, D. J., Shevell, D. E., Gluud, L. L., Karsdal, M. A., Aithal, G. P., & Schattenberg, J. M. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100317 · Cited by 44
“3 ng/ml.(15,18,23,38,39) Two of the studies included data on PRO-C3 in detecting (fibrotic) NAFLD/NASH and found thresholds of 14.”
BackgroundSelf-citationThiele, M. S., Johansen, S., Gudmann, N. S., Madsen, B. S., Kjærgaard, M., Nielsen, M. J., Leeming, D. J., Jacobsen, S., Bendtsen, F., Møller, S., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16567 · Cited by 47
Self-citationIncretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Karsdal, M. A., Kraus, V. B., Shevell, D. E., Bay‐Jensen, A., Schattenberg, J. M., Surabattula, R., & Schuppan, D. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102706 · Cited by 41
Self-citationBrown, E. A., Minnich, A., Sanyal, A. J., Loomba, R. S., Du, S., Schwarz, J., Ehman, R. L., Karsdal, M. A., Leeming, D. J., Cizza, G., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100661 · Cited by 44
Self-citationHan, J. W., Kim, H. Y., Yu, J. H., Kim, M. N., Chon, Y. E., An, J., Jin, Y., Choi, M., Kim, S. U., Lee, H. A., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0330 · Cited by 44
Binet, Q., Loumaye, A., Preumont, V., Thissen, J., Hermans, M. P., & Lanthier, N. (2022) · Acta gastro-enterologica belgica · doi:10.51821/85.2.9775 · Cited by 45
Armandi, A., Rosso, C., Nicolosi, A., Caviglia, G. P., Abate, M. L., Olivero, A., D’Amato, D., Vernero, M., Gaggini, M., Saracco, G. M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030635 · Cited by 33
“Current evidence fro the literature assesses the role of these two peptides for the quantification of liver fibrogenesis [14,15].”
BackgroundMethodSelf-citationTirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
“Therefore, a requirement for further evaluation is needed to support the findings of this study [47-49].”
BackgroundLin, C., Adhikary, P., & Cheng, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.008 · Cited by 35
Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease
Lai, J., Wang, H. L., Zhang, X., Wang, H., & Liu, X. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0339-ra · Cited by 29
Self-citationHarrison, S. A., Baum, S. J., Gunn, N., Younes, Z. H., Kohli, A., Patil, R., Koziel, M. J., Chera, H., Zhao, J., & Chakravarthy, M. V. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001375 · Cited by 26
“An absolute reduction of;2 ng/mL in plasma Pro-C3, a fibrogenesis marker, was associated with 1-stage histologic improvement in fibrosis after 18 months of pioglitazone treatment in NASH subjects (31).”
BackgroundNielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., Irving, W. L., Karsdal, M. A., Patel, K., Leeming, D. J., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100743 · Cited by 26
Self-citationLassen, P. B., Nori, N., Bédossa, P., Genser, L., Aron‐Wisnewsky, J., Poitou, C., Surabattula, R., Nielsen, M. J., Karsdal, M. A., Leeming, D. J., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab897 · Cited by 17
Self-citationExosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
Qi, X., & Lai, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113501 · Cited by 17
“PRO-C3 has been shown to be correlated with the fibrosis stage and additionally to be related to disease activity [5,47].”
BackgroundMethodSelf-citationLiu, M., Qiu, H., Zhang, W., Mei, T., Tang, S., Gao, Y., Zhu, Y., Huang, X., & Yu, H. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16240 · Cited by 15
Serum biomarkers for liver fibrosis assessment
Maroto‐García, J., Álvarez, A. M., de Pedro, M. P. S., Soto, A. B., & González, Á. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0081 · Cited by 25
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 12
Self-citationReese‐Petersen, A. L., Nielsen, S. H., Sand, J. M. B., Schattenberg, J. M., Bugianesi, E., & Karsdal, M. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15615 · Cited by 12
“26 This is a noteworthy finding, as this specific patient population exhibits different phenotypic traits compared with patients without T2D, and diagnostic tools tend to underperform in this population.”
BackgroundSelf-citationNon-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes
Alhinai, A., Patel, K., Fonseca, V. A., & Sebastiani, G. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107978 · Cited by 11
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers
Terracciani, F., Falcomatà, A., Gallo, P., Picardi, A., & Gentilucci, U. V. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00934-0 · Cited by 9
“Finally, as suggested by recent studies [104] [105], the potential role of Pro-C3 in monitoring fibrosis and treatment response over time deserves to be extensively investigated.”
BackgroundArmandi, A., Rosso, C., Younes, R., Leeming, D. J., Karsdal, M. A., Caviglia, G. P., Pérez-Díaz-del-Campo, N., D’Amato, D., Abdulle, A., Nicolosi, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020650 · Cited by 11
“PROC3 was assessed by a competitive ELISA assay (Nordic Bioscience Laboratory, Herlev, Denmark) [13,14].”
MethodSelf-citationCohen, C. C., Castillo‐Leon, E., Farris, A. B., Caltharp, S. A., Cleeton, R. L., Sinclair, E. M., Shevell, D. E., Karsdal, M. A., Nielsen, M. J., Leeming, D. J., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1766 · Cited by 9
“This suggests that, although in adults PRO- C3 is considered to be a marker of active fibrogenesis,(10,11,12,14) growth spurts confound the interpretation of PRO- 3 levels in children.”
BackgroundSelf-citationBrodosi, L., Petroni, M. L., & Marchesini, G. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2208746 · Cited by 7
“The low serum adiponectin levels at baseline, markers predictive of liver injury in NASH [18], increased significantly with tirzepatide in a dose-response fashion, whereas the decrease in Pro-C-3 was in the same range of magnitude of that observed for one stage decrease of fibrosis in another intervention trial [19].”
BackgroundWang, L. Y., & Wang, Y. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s593387 · Cited by 8
“52 ADAPT, a non-invasive composite algorithm, incorporates PRO-C3, T2DM status, platelet count, and age.”
Rasmussen, D. G. K., Hansen, M. K., Frederiksen, P., Luo, Y., Pehrsson, M., Neal, B. C., Karsdal, M. A., & Genovese, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15761 · Cited by 5
Self-citationDual GLP-1/GIP Agonist Tirzepatide for Diabetes and Obesity: A Review of the Evidence
Wardeh, R., Elbo-Iswadi, T. H., Alsharayri, H. M. H., Rashid, F., Alhashemi, N., & Bashier, A. M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1775966 · Cited by 6
Biomarcadores séricos para la evaluación de la fibrosis hepática
Maroto‐García, J., Moreno‐Álvarez, A., de Pedro, M. P. S., Soto, A. B., & González, Á. (2024) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0172 · Cited by 4
“En un estudio reciente se ha identi fi cado al propéptido N-terminal del procolágeno tipo III (PCIIINP), uno de los principales componentes del tejido conectivo, como un buen marcador de fi brosis hepática en pacientes con diabetes tipo 2 [121].”
BackgroundLin, X., Lan, Q., Liu, Y., Dong, X., & Wu, L.-Y. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-03047-5 · Cited by 3
Mrosewski, I., Mantel, V., Urbank, M., Schulze-Tanzil, G. G., Werner, C., Gögele, C., Kokozidou, M., & Bertsch, T. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40826 · Cited by 3
Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac186 · Cited by 3
“The performance of FIB-4 may be improved in patients with T2DM by using a higher cutoff (≥1.67 vs >1.3) that reduces the indeterminate zone by about half, decreasing the need for specialist referral (5).”
BackgroundSelf-citationLi, H., Xu, X., Yi, T. C., Zheng, T., & Yan, T. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-21-3760 · Cited by 3
Karsdal, M. A., Bay‐Jensen, A., Rasmussen, D. G. K., Krag, A. A., Johansen, S., Anstee, Q. M., Leeming, D. J., Genovese, F., Sanyal, A. J., Bager, C. L., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.016 · Cited by 1
Self-citationCollagens of the third and fourth types in various forms of alcoholic liver disease
Дуданова, О. П., Родина, А. С., Шубина, М. Э., Валерьевна, К. И., & Topchieva, L. V. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-207-11-128-134 · Cited by 2
Wang, Z., Wan, D., Xu, M., & Jiang, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0993 · Cited by 1
Han, J. W., & Jun, D. W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1160 · Cited by 1
Schattenberg, J. M., & Geier, A. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00648-1
Brèves: Fragments de procollagènedans le sang : nouveauxmarqueurs de la fibrose hépatique ?
(2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30121-x
Feng, X., Fu, J., Liu, Y., & Wang, F. (2025) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2025.101904
Comparative Efficiency of APRI vs. FIB-4 in Detecting Advanced Liver Fibrosis in NAFLD and NASH
Noureen, S., Fatima, H., Butt, A. H., Zia, A., Abid, M. H., & Malik, I. (2025) · Biological and Clinical Sciences Research Journal · doi:10.54112/bcsrj.v6i6.1874
Nammi, J., Southall, W. R., Huynh, K., Smith, E., Diffalha, S. A., Cusi, K. J., Gray, M., & Bril, F. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.09.003
Self-citationTufael, D., Mujahid, M. H., Akter, M. F., Salam, T., Siddique, M. A. B., Bari, K. F., Debnath, A., & Nath, N. D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0358858
“These findings are consistent with previous studies [30,38–40], which reported that chronic inflammation and insulin resistance jointly contribute to the development of fibrosis and hepatocellular carcinoma (HCC) in HCV infection.”
Metadata
- Authors
- Bril, F., Leeming, D. J., Karsdal, M. A., Kalavalapalli, S., Barb, D., Lai, J., Rabe, M., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Nordic Bioscience (Denmark) (DK)
- Corresponding author
- Cusi, Kenneth
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-05-21
- Volume
- 42
- Issue
- 7
- Pages
- 1348-1351
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2946261704
- Cited by
- 52
- References
- 17
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 10 · 2023: 9 · 2022: 7 · 2021: 11 · 2020: 8 · 2019: 2
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- liver fibrosis, type 2 diabetes, PRO-C3, non-invasive fibrosis markers, APRI, FIB-4, fibrosis staging, liver biopsy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Biopsy, Diabetes Mellitus, Type 2, Female, Humans, Liver Cirrhosis, Longitudinal Studies, Male, Middle Aged, Magnetic Resonance Spectroscopy, Peptide Fragments, Platelet Count, Predictive Value of Tests, Procollagen, Sensitivity and Specificity, Biomarkers, Collagen Type III, Collagen Type V, Collagen Type VI, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.